SCHEMBL3338699

SCHEMBL3338699

CNC(=O)CN(C)c1n[nH]c2ccc(-c3cc(-c4ccccc4OCC(C)C)[nH]c(=O)n3)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.36
CDC7 O00311 4/20 0.36
DHODH Q02127 2/20 0.35
XDH P47989 7/20 0.34
DYRK1A Q13627 2/20 0.34
MAPK13 O15264 1/20 0.33
DAPK3 O43293 1/20 0.33
ROCK2 O75116 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
CDK1 P06493 1/20 0.33
FGFR1 P11362 1/20 0.33
RPS6KB1 P23443 1/20 0.33
CDK2 P24941 1/20 0.33
MAPK1 P28482 1/20 0.33
FLT4 P35916 1/20 0.33
CSNK1A1 P48729 1/20 0.33
CSNK1D P48730 1/20 0.33
MAPKAPK2 P49137 1/20 0.33
CLK2 P49760 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14080581 0.86 CDC7 (0.34) PIM1CDC7DHODHXDHDYRK1A
SCHEMBL3338697 0.84 GSK3B (0.49) PIM1CDC7DHODHDYRK1AMAPK13
SCHEMBL3342410 0.82 CDC7 (0.41) PIM1CDC7DHODHXDHDYRK1A
SCHEMBL3339497 0.82 GSK3B (0.45) PIM1CDC7DHODHDYRK1AMAPK13
SCHEMBL3339626 0.81 XDH (0.44) PIM1CDC7DHODHXDHDYRK1A
SCHEMBL3338698 0.81 MAPK1 (0.41) PIM1CDC7DHODHXDHDYRK1A
SCHEMBL13305018 0.81 DYRK1A (0.40) PIM1CDC7DHODHXDHDYRK1A
SCHEMBL14023056 0.79 PIM1 (0.41) PIM1CDC7DHODHXDHDYRK1A
SCHEMBL14080580 0.78 MAPK1 (0.36) PIM1CDC7DHODHXDHDYRK1A
SCHEMBL3337518 0.78 CDC7 (0.40) PIM1CDC7DHODHXDHDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074114-B1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS INC (US) 2013-03-06 EP claimed
US-8324231-B2 Pyrimidinones as casein kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-12-04 US claimed
US-20100144770-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. (US) 2010-06-10 US claimed
EP-2074114-B1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS INC (US) 2013-03-06 EP disclosed
US-8324231-B2 Pyrimidinones as casein kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-12-04 US disclosed
US-20100144770-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. (US) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144770-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators CSNK2A1, CSNK2A2, CSNK1A1 PIM1 579/4885CDC7 532/4885DHODH 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.